Focused radiation doses put to the test for large brain tumors

NCT ID NCT03726359

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial investigates the safest and most effective dose of fractionated stereotactic radiation therapy (FSRT) for people with large brain metastases (tumors that have spread from other cancers). Participants receive radiation in several small doses over 1.5 to 2 weeks. The study aims to find the maximum dose that can be given without causing severe side effects, and to measure how well the tumors respond. Results will help design future larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fractionated Stereotactic Radiation Therapy (FSRT)
What this could lead to
If successful, this could establish a standard dosing regimen for FSRT in large brain metastases, improving tumor control while limiting side effects.
What could go wrong
This is an early-phase dose-finding study with only 30 participants, so results may not apply broadly. There is a risk of radiation-related toxicities, including brain swelling or necrosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.